Tag results:

EGFR

Claudin1 Decrease Induced by 1,25-Dihydroxy-Vitamin D3 Potentiates Gefitinib Resistance Therapy through Inhibiting AKT Activation-Mediated Cancer Stem-Like Properties in NSCLC Cells

[Cell Death Discovery] Researchers performed GEO dataset analysis and identified that claudin1 was a critical regulator of epidermal growth factor receptor tyrosine kinase inhibitors resistance in NSCLC cells.

Small Cell Lung Cancer Transformation: From Pathogenesis to Treatment

[Seminars in Cancer Biology] The authors review the advancements in transformed SCLC, including clinical and pathological characteristics, and the potential effective treatment after SCLC transformation, aiming to give a better understanding of transformed SCLC and provide support for clinical uses.

US FDA Approves FoundationOne®CDx as a Companion Diagnostic for EGFR Therapeutics Targeting Exon 19 Deletions or Exon 21 Substitutions in Non-Small Cell Lung Cancer

[Foundation Medicine, Inc.] Foundation Medicine, Inc. announced it has received approval from the US FDA for FoundationOne®CDx to be used as a companion diagnostic to identify patients with NSCLC.

Glycosphingolipids in Human Embryonic Stem Cells and Breast Cancer Stem Cells, and Potential Cancer Therapy Strategies Based on Their Structures and Functions

[Glycoconjugate Journal] The authors indicate that GD3 synthase contributes to gefitinib resistance in epidermal growth factor receptor-positive breast cancer cells, and is a potentially useful therapeutic target in drug-resistant breast cancers.

Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid Leukemia

[Future Oncology] The authors take stock of the relationship between epidermal growth factor receptor (EGFR) mutations and PD-1 and its ligand receptor 1expression and summarize the important clinical studies on immunotherapy-inhibitor-based treatment in patients with EGFR-TKI-resistant NSCLC.

Integration of Liquid Biopsy and Pharmacogenomics for Precision Therapy of EGFR Mutant and Resistant Lung Cancers

[Molecular Cancer] Scientists appraise current literature, opportunities, and challenges associated with liquid biopsy and pharmacogenomic testing as precision therapy tools in the management of epidermal growth factor receptor (EGFR) mutant and resistant lung cancers.

Popular